Home Cart Sign in  
Chemical Structure| 389574-19-0 Chemical Structure| 389574-19-0

Structure of Prasugrel HCl
CAS No.: 389574-19-0

Chemical Structure| 389574-19-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Prasugrel HCl is a platelet inhibitor with IC50 value of 1.8 μM.

Synonyms: PCR 4099 hydrochloride; Prasugrel hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Prasugrel HCl

CAS No. :389574-19-0
Formula : C20H21ClFNO3S
M.W : 409.90
SMILES Code : FC1=CC=CC=C1C(C(C2CC2)=O)N3CCC4=C(C3)C=C(S4)OC(C)=O.Cl
Synonyms :
PCR 4099 hydrochloride; Prasugrel hydrochloride
MDL No. :MFCD11867705
InChI Key :JALHGCPDPSNJNY-UHFFFAOYSA-N
Pubchem ID :10158453

Safety of Prasugrel HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Prasugrel HCl

GPCR

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.20mL

2.44mL

1.22mL

24.40mL

4.88mL

2.44mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Baker WL, White CM. Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes. Am J Cardiovasc Drugs. 2009;9(4):213-29.

[2]Sugidachi A, Ogawa T, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51. Epub 2007 Apr 19.

[3]Conran N, Rees DC. Prasugrel hydrochloride for the treatment of sickle cell disease. Expert Opin Investig Drugs. 2017 Jul;26(7):865-872

[4]Khan MS, Memon MM, Usman MS, Alnaimat S, Khan SU, Khan AR, Yamani N, Fugar S, Mookadam F, Krasuski RA, Doukky R. Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2019 Oct;19(5):465-476

[5]Xia P, He C, Chen L, Zou L, Sun S, Cui P, Wang W. Efficacy and safety of prasugrel therapy for intracranial aneurysms with endovascular treatment: A meta-analysis. J Neurol Sci. 2019 Feb 15;397:174-178

[6]Gunarathne A, Hussain S, Gershlick AH. Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. Expert Rev Cardiovasc Ther. 2016 Nov;14(11):1215-1226

[7]Spartalis M, Tzatzaki E, Spartalis E, Damaskos C, Athanasiou A, Moris D, Politou M. The role of prasugrel in the management of acute coronary syndromes: a systematic review. Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4733-4743

 

Historical Records

Categories